AC Immune

ACIU

Market cap $357M

Overview Fund Trends Analyst Outlook Journalist View

3.47 USD

--0.08

2.25%

At close Updated Oct 13, 4:00 PM EDT

Pre-market

After hours

3.45

--0.02

0.58%

1 day

-2.25%

5 days

-3.88%

1 month

39.92%

3 months

66.83%

6 months

128.29%

Year to date

21.75%

1 year

8.78%

5 years

-30.46%

10 years

-77.84%

About: AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Employees: 172

Healthcare Biotechnology